| Literature DB >> 30008604 |
Sang Il Kim1, Joo Hee Yoon1, Dong Choon Park1, Dong Sup Lee2, Seung Ju Lee2, Hyun Sop Choe2, Jin Hwi Kim3, Tae Chul Park3, Sung Jong Lee1.
Abstract
This study aimed to determine the role of asymptomatic bacterial sexually transmitted infections (STIs), such as Chlamydia trachomatis (Ct), Mycoplasma genitalium (Mg), Mycoplasma hominis (Mh), and Ureaplasma urealyticum (Uu) in human papillomavirus (HPV) infection. In total, 264 asymptomatic outpatients aged between 21 and 80 years were prospectively enrolled in this study during routine gynecological screening tests. Specimens collected with a Cervex Brush were routinely analyzed with the Hybrid Capture 2 assay for HPV. Simultaneously, a specimen obtained with an endocervical swab was used to detect Ct and Mg with a monoplex real-time polymerase chain reaction (PCR) and to confirm Mh and Uu with a Mycoplasma IST 2 kit. The detection rates (%) of HPV, Ct, Mg, Mh, and Uu were 82/264 (31.1), 6/264 (2.3), 5/264 (1.9), 16/264 (6.1), and 95/264 (36.0), respectively. Of 95 Uu, 32 (33.7%) showed high density colonization (HDC, ≥104 color-changing units/mL). HDC-Uu was significantly associated with HPV infection (p=0.014, chi-square test). Mg infection and Mh infection were not associated with HPV infection (p=0.981 and p=0.931, chi-square test). Age was not associated with HPV infection or bacterial infection. Our data suggested that asymptomatic HDC-Uu was closely associated with HPV infection. Therefore, simultaneous evaluation for Uu and HPV should be performed during gynecological screening, even in asymptomatic individuals.Entities:
Keywords: Mycoplasma; Ureaplasma urealyticum; human papillomavirus
Mesh:
Year: 2018 PMID: 30008604 PMCID: PMC6036102 DOI: 10.7150/ijms.26523
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Baseline characteristics of study population (N=264)
| HPV negative (n=182) | HPV positive (n=82) | Total (n=264) | OR | ||
|---|---|---|---|---|---|
| 51.5±8.06 | 49.11±12.55 | 50.76±11.04 | 0.376‡, -2.234 ~ 5.865 | ||
| 1 partner | 155 (85.2%) | 39 (47.6%) | 194 (73.5%) | 1.00 | |
| 2 partners | 14 (7.7%) | 20 (24.4%) | 34 (12.9%) | 5.678* | 0.001§, 2.634 ~ 12.24 |
| 3 or more partners | 13 (7.1%) | 23 (28.0%) | 36 (13.6%) | 7.032* | 0.001§, 3.270 ~ 15.12 |
| Nulliparous | 43 (23.6%) | 22 (26.8%) | 65 (24.6%) | 1.00 | |
| Multiparous | 139 (76.4%) | 60 (73.2%) | 199 (75.4%) | 1.54* | 0.330§, 0.641 ~ 3.715 |
| 25 (13.7%) | 23 (28.0%) | 48 (18.2%) | 2.29† | 0.198§, 0.752 ~ 6.948 | |
Each mean data was presented with standard deviation
OR* is the odds ratio compared with the first category, and OR† is the odds ratio between HPV negative and positive group.
p-value‡ and p-value§ were measured by t-student test and Chi-square test, respectively.
Characteristics of human papillomavirus infection, cervical cytology and sexually transmitted bacterial infection by age (N=264)
| Age distribution | 21~50 (n=139) | 51~80 (n=125) | OR | 95% CI | |||
|---|---|---|---|---|---|---|---|
| HPV | |||||||
| HPV negative (n=182) | 93/139 (66.9%) | 89/125 (71.2%) | 1.00 | ||||
| HPV positive (n=82) | 46/139 (33.1%) | 36/125 (28.8%) | 1.223, | 0.4516* | 0.724 - 1.652 | ||
| Cytology | |||||||
| Negative cytology (n=195) | 101/139 (72.6%) | 94/125 (75.2%) | 1.00 | ||||
| Low grade abnormality+ (n=28) | 14/139 (10.1%) | 14/125 (11.2%) | 0.888 | 0.766* | 0.406 - 1.945 | ||
| High grade abnormality‡ (n=41) | 24/139 (17.3%) | 17/125(13.6%) | 1.326 | 0.412* | 0.675 - 2.603 | ||
| Bacterial infection | |||||||
| 4/139 (2.9%) | 2/125 (1.6%) | 1.822 | 0.487* | 0.328 - 10.13 | |||
| 4/139 (2.9%) | 1/125 (0.8%) | 3.674 | 0.216* | 0.405 - 33.34 | |||
| <104CCU/ml (n=63) | 32/139 (23.0%) | 31/125 (24.8%) | 0.907 | 0.735* | 0.515 - 1.598 | ||
| >104CCU/ml (n=32) | 18/139 (12.9%) | 14/125 (11.2%) | 1.179 | 0.664* | 0.560 - 2.483 | ||
| <104CCU/ml (n=13) | 4/139 (2.9%) | 9/125 (7.2%) | 0.382 | 0.105* | 0.115 - 1.273 | ||
| >104CCU/ml (n=3) | 1/139 (0.7%) | 2/125 (1.6%) | 0.446 | 0.500* | 0.040 - 4.978 |
Data in bracket was presented as positive cases/all cases, percentage
* Chi-squared test; +Low grade: ASCUS, AGUS, LSIL; ‡High grade: ASC-H, HSIL
Relationship between sexually transmitted bacterial infections and HPV infection (N=264)
| Bacterial infection | HPV negative (n=182) | HPV positive (n=82) | ||
|---|---|---|---|---|
| 4 (2.2%) | 2 (2.4%) | 0.903*, 1.113 0.199-6.202 | ||
| 2 (1.1%) | 3 (3.7%) | 0.158*, 3.418, 0.559-20.86 | ||
| <104 CCU/ml (n=63) | 40 (22.0%) | 23 (28.0%) | 0.284*, 1.384, 0.762-2.512 | |
| >104 CCU/ml (n=32) | 16 (8.8%) | 16 (19.5%) | 0.014*, 2.515, 1.189-5.322 | |
| <104 CCU/ml (n=13) | 9 (4.9%) | 4 (4.9%) | 0.981*, 0.985, 0.294-3.299 | |
| >104 CCU/ml (n=3) | 2 (1.1%) | 1 (1.2%) | 0.931*, 1.111, 0.099-12.44 |
Each value was presented as negative/positive.
*Chi-squared test
†Chlamydia trachomatis
‡Mycoplasma genitalium
§Ureaplamsa urealyticum
∥Mycoplasma hominis
Antimicrobial susceptibility pattern of Ureaplasma urealyticum and Mycoplasma hominis in asymptomatic sexually active women (N=111*)
| S† (%) | I‡ (%) | R§ (%) | S† (%) | I‡ (%) | R§ (%) | |
| Doxycycline | 95(100.0) | 0 (0.0) | 0 (0.0) | 16(100.0) | 0 (0.0) | 0 (0.0) |
| Josamycin | 95(100.0) | 0 (0.0) | 0 (0.0) | 16(100.0) | 0 (0.0) | 0 (0.0) |
| Ofloxacin | 38 (40.0) | 48 (50.5) | 8 (8.4) | 14 (87.5) | 2 (12.5) | 0 (0.0) |
| Erythromycin | 83 (87.4) | 10 (10.5) | 2 (2.1) | 0 (0.0) | 0 (0.0) | 16(100.0) |
| Tetracycline | 95(100.0) | 0 (0.0) | 0 (0.0) | 16(100.0) | 0 (0.0) | 0 (0.0) |
| Ciprofloxacin | 10 (10.5) | 39 (41.1) | 46 (48.4) | 11 (68.8) | 2 (12.5) | 2 (12.5) |
| Azithromycin | 77 (81.0) | 18 (18.9) | 0 (0.0) | 0 (0.0) | 4 (25.0) | 12 (75.0) |
| Clarithromycin | 93 (97.9) | 0 (0.0) | 2 (2.1) | 0 (0.0) | 0 (0.0) | 16(100.0) |
| Pristinamycin | 95(100.0) | 0 (0.0) | 0 (0.0) | 16(100.0) | 0 (0.0) | 0 (0.0) |
*Among 264 patients, 95 patients were positive for Ureaplasma urealyticum and 16 patients were positive for Mycoplasma hominis. Antibiotics susceptibility was tested only for Ureaplasma urealyticum and/or Mycoplasma hominis positive patients.
†Susceptible
‡Intermediate
§Resistant
Relationship between bacterial infection and HPV infection
| Number | Parameter | Key findings | Authors |
|---|---|---|---|
| 1 | Bacterial infection, CIN | Szostek et al. [12] | |
| 2 | Bacterial infection, HPV infection | Correlation between | Pisani et al. [10] |
| 3 | Bacterial infection, HPV infection, Cytology | Lukic et al. [2] | |
| 4 | Bacterial infection, HPV infection | Significant association between HPV and | Verteramo et al. [3] |
| 5 | Bacterial infection, HPV infection | Significant association between HPV and | Zheng et al. [13] |
| 6 | Bacterial infection, HPV infection | 5 times increased risk of HPV infection in case of | Biernat-Sudolska et al. [14] |
| 7 | Bacterial infection, HPV infection, CIN | Higher positive rate of | Xiaolei et al. [15] |
| 8 | Bacterial infection, HPV infection | 6 times increased risk of | Camporiondo et al. [16] |
| 9 | Bacterial infection, HPV infection, CIN | Strong correlation between coinfection of | Drago et al. [17] |
| 10 | Bacterial infection, HPV infection | Significant association between HPV and bacterial vaginosis such as, | Liu et al. [18] |
| 11 | Bacterial infection, Cytology | Significant relationship between | Okodo et al. [19] |
| 12 | Bacterial infection, HPV infection, Oncogene | Stimulation of | Szostek et al. [20] |
*Ureaplasma Urealyticum
+Cervical intraepithelial neoplasia
‡Chlamydia Trachomatis
§Ureaplasma Parvum